|
|
2100 Powell St.
Emeryville, CA 94608 USA
phone:510-597-6500
fax:510-597-6600
|
|
| Symbol |
ONXX |
| Exchange |
NASDAQ |
| Founded |
1992 |
| Employees |
89 |
|
|
| www.onyx-pharm.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Novel cancer therapies utilizing two technology platforms |
|
| Management |
| N. Anthony (Tony) Coles, M.D., M.P.H., President, Chief Executive Officer and Member of the Board; Laura A. Brege, Executive Vice President and Chief Operating Officer; Matthew K. Fust, Executive Vice President and Chief Financial Officer; Michael G. Kauffman, M.D., Ph.D., Interim Chief Medical Officer; Juergen Lasowski, Ph.D., Senior Vice President, Corporate Development |
| |
|
|
|
|
|
|
|
| Keywords |
| sorafenib, angiogenesis, carcinoma, interleukin-2, myocardial |
|
|
|
| Description |
|
Onyx Pharmaceuticals, Inc. is engaged in the discovery and development of novel cancer therapies utilizing two technology platforms, small molecules that inhibit the proteins involved in excess growth signaling, and therapeutic viruses that selectively replicate in cells with cancer-causing genetic mutations. The Company is developing a novel small molecule compound, BAY 43-9006, in collaboration with Bayer Pharmaceuticals Corporation and is utilizing its proprietary virus technologyto develop ONYX-411, a second-generation product that targets cancers with abnormal function of the retinoblastoma tumor-suppressor gene. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
